Molecular and Biochemical Therapeutic Strategies for Duchenne Muscular Dystrophy

Significant progress has been achieved in understanding Duchenne muscular dystrophy (DMD) mechanisms and developing treatments to slow disease progression. This review article thoroughly assesses primary and secondary DMD therapies, focusing on innovative modalities. The primary therapy addresses th...

Full description

Saved in:
Bibliographic Details
Main Authors: Lakshmi Krishna (Author), Akila Prashant (Author), Yogish H. Kumar (Author), Shasthara Paneyala (Author), Siddaramappa J. Patil (Author), Shobha Chikkavaddaragudi Ramachandra (Author), Prashant Vishwanath (Author)
Format: Book
Published: MDPI AG, 2024-07-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_37e9efa85a2e4d2d8ab344262e2c12a8
042 |a dc 
100 1 0 |a Lakshmi Krishna  |e author 
700 1 0 |a Akila Prashant  |e author 
700 1 0 |a Yogish H. Kumar  |e author 
700 1 0 |a Shasthara Paneyala  |e author 
700 1 0 |a Siddaramappa J. Patil  |e author 
700 1 0 |a Shobha Chikkavaddaragudi Ramachandra  |e author 
700 1 0 |a Prashant Vishwanath  |e author 
245 0 0 |a Molecular and Biochemical Therapeutic Strategies for Duchenne Muscular Dystrophy 
260 |b MDPI AG,   |c 2024-07-01T00:00:00Z. 
500 |a 10.3390/neurolint16040055 
500 |a 2035-8377 
520 |a Significant progress has been achieved in understanding Duchenne muscular dystrophy (DMD) mechanisms and developing treatments to slow disease progression. This review article thoroughly assesses primary and secondary DMD therapies, focusing on innovative modalities. The primary therapy addresses the genetic abnormality causing DMD, specifically the absence or reduced expression of dystrophin. Gene replacement therapies, such as exon skipping, readthrough, and gene editing technologies, show promise in restoring dystrophin expression. Adeno-associated viruses (AAVs), a recent advancement in viral vector-based gene therapies, have shown encouraging results in preclinical and clinical studies. Secondary therapies aim to maintain muscle function and improve quality of life by mitigating DMD symptoms and complications. Glucocorticoid drugs like prednisone and deflazacort have proven effective in slowing disease progression and delaying loss of ambulation. Supportive treatments targeting calcium dysregulation, histone deacetylase, and redox imbalance are also crucial for preserving overall health and function. Additionally, the review includes a detailed table of ongoing and approved clinical trials for DMD, exploring various therapeutic approaches such as gene therapies, exon skipping drugs, utrophin modulators, anti-inflammatory agents, and novel compounds. This highlights the dynamic research field and ongoing efforts to develop effective DMD treatments. 
546 |a EN 
690 |a muscular dystrophy Duchenne 1 
690 |a CRISPR-Cas systems 2 
690 |a CRISPR-Cas systems 3 
690 |a histone deacetylase inhibitors (HDACis) 
690 |a drugs investigational 
690 |a Medicine 
690 |a R 
690 |a Internal medicine 
690 |a RC31-1245 
690 |a Neurosciences. Biological psychiatry. Neuropsychiatry 
690 |a RC321-571 
690 |a Neurosciences. Biological psychiatry. Neuropsychiatry 
690 |a RC321-571 
655 7 |a article  |2 local 
786 0 |n Neurology International, Vol 16, Iss 4, Pp 731-760 (2024) 
787 0 |n https://www.mdpi.com/2035-8377/16/4/55 
787 0 |n https://doaj.org/toc/2035-8377 
856 4 1 |u https://doaj.org/article/37e9efa85a2e4d2d8ab344262e2c12a8  |z Connect to this object online.